George Touma Highlights DCB-BIF Trial: Drug-Coated Balloons Improve Outcomes in Coronary Bifurcation PCI
George Touma, Interventional Cardiologist at St George Private Cardiology, posted on LinkedIn:
” What is the DCB-BIF Trial?
The DCB-BIF (Drug-Coated Balloon in Bifurcations) trial is the first well powered, multicenter randomized study comparing drug-coated balloon (DCB) angioplasty versus conventional non-compliant balloon (NCB) angioplasty for the side branch (SB) in patients with true but “simple” coronary bifurcation lesions treated using a provisional stenting strategy.
Conducted across 22 centers in China, Indonesia, Italy, and Korea, it enrolled 784 patients.
Study Design and Patients
• Included patients with true bifurcations (Medina 1,1,1; 0,1,1; or 1,0,1) and SB ostial stenosis ≥70% after main vessel (MV) stenting and proximal optimization (POT).
• Randomized 1:1 into two groups:
– DCB arm – SB treated with a paclitaxel-coated balloon
– NCB arm – SB treated with a standard non-compliant balloon
• Primary endpoint: 1-year MACE (cardiac death, target-vessel MI, clinically driven TLR).
• Patients: median age 65 years, 23% women.
Key Findings
MACE at 1 year:
• 7.2% in the DCB group
• 12.5% in the NCB group
Benefit driven by lower target-vessel MI.
Rates of cardiac death, TLR, procedural success, two-stent crossover, all-cause death, and stent thrombosis were similar.
Interpretation and Significance
• DCB for SB angioplasty improves outcomes compared to conventional ballooning in this scenario.
• As the first large RCT powered for clinical outcomes, DCB-BIF provides evidence for incorporating DCBs into bifurcation PCI strategies.
Broader Context and Research
• Before DCB-BIF: evidence was limited to small RCTs and meta-analyses focused on angiographic outcomes like late lumen loss (LLL). These suggested better SB patency and possible MI reduction, but lacked power.
• Meta-analysis of 5 RCTs (~1,255 patients): DCBs reduced MI risk (RR = 0.56; p=0.01), though no significant differences in overall MACE, TLR, or mortality.
The Five RCTs used in this meta analysis:
1. Herrador et al., 2013 (Spain) – Non-randomized (NRCT) study using SeQuent Please paclitaxel-eluting balloon.
2. Zong et al., 2018 (China) – RCT, SeQuent Please paclitaxel-eluting balloon.
3. Zhang et al., 2019 (China) – NRCT, SeQuent Please paclitaxel-eluting balloon.
4. Jing et al., 2020 (China) – RCT, Bingo paclitaxel-eluting balloon.
5. Bu et al., 2021 (China) – RCT, DCB (unspecified brand).
• PEPCAD-BIF trial (~64 patients): showed less late lumen loss with DCB vs plain balloons.
• Ongoing trials (e.g., OCVC-BIF) are testing additional DCB use after kissing balloon inflation versus standard approaches, aiming to refine bifurcation PCI strategies.
Take-Home Message
The DCB-BIF trial establishes DCB angioplasty as a clinically superior side-branch strategy in provisional bifurcation PCI – delivering fewer MIs. Its my default strategy.”
Stay updated with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies